Bayer Faces Massive Compensation: $78 Million Ruling Shocks Market, Roundup Herbicide Sparks Cancer Panic
Bayer AG (BAYGn.DE) has been ordered to pay up to $78 million in damages to a Pennsylvania man who claimed he developed a deadly form of cancer from using Bayer's Roundup herbicide. The verdict was reached Thursday by a state court jury in Philadelphia. Bayer had previously won a string of victories in the court, winning 14 of the 20 previous cases against Roundup. However, the company has also been hit with several major judgments, including a $1.56 billion judgment in November, which was later reduced to $611 million, and a $2.25 billion judgment in January, which was later reduced to $400 million.
Tom Kline and Jason Itkin, lawyers for plaintiffs William Melissen and his wife, Margaret, sharply criticized Bayer in a statement, saying the company "has a disregard for people's safety, They acted recklessly "and" have yet to learn from these proceedings and change their ways."
The jury awarded William Melison $3 million in compensatory damages and up to $75 million in punitive damages. In a later statement, Bayer said it disagreed with the jury's verdict because it conflicted with "overwhelming scientific evidence and the consensus of global regulators and their scientific assessments."
Bayer said it was confident of reducing the amount of punitive damages during the appeal process. According to the U.S. Supreme Court, punitive damages generally cannot exceed nine times the amount of compensatory damages. The Melissons, who filed their lawsuit in 2021, claim that William, like the other Roundup plaintiffs, developed a form of non-Hodgkin's lymphoma from glyphosate exposure. Glyphosate was the active ingredient in Roundup products for home use until it was discontinued last year.
Melison said he used the product at home and in the workplace from 1992 to 2020, until he was diagnosed with cancer. He claims glyphosate and other chemicals in Roundup caused his illness. Bayer insists glyphosate does not cause cancer and that the lawsuits are without merit. As part of its $63 billion acquisition of agrochemical company Monsanto in 2018, Bayer acquired the Roundup brand.
The German company settled most of the outstanding lawsuits in 2020, paying $10.9 billion, but still faces about 58,000 similar claims, according to its latest financial report.
Looking for chemical products? Let suppliers reach out to you!
2026-06-24
-
Life Sciences Industry Overview
The coverage spans the global life sciences industry across pharmaceuticals and food & nutrition, tracking the shift from lowest-cost sourcing to supply continuity, quality, and risk management, along with product trends and the growing edge of differentiated, globally capable players.Published in: June.2026
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
FDA Approves Datopotamab Deruxtecan for Second Indication 45 Percent Response Rate in EGFR Mutant Lung Cancer
-
UK Parliament Approves Assisted Dying Bill 7500 Could Seek Euthanasia Annually
-
4 Pharma Firms Lose Licenses in Jammu and Kashmir Amid Illegal Drug Sales Crackdown
-
Over 100 Foreign Pharma Executives Join Chinese Firms in 5 Years Industry Faces Key Challenges
-
Merck’s New CMV Drug Approved in China Targets Nearly 40000 HSCT Patients
-
Trump Warns of 200 Percent Tariffs on Pharma Companies by August 1 India Trade Deal Among Top Priorities
-
Emcure Seals Exclusive Deal for Sanofi’s Oral Diabetes Brands Millions of Indian Patients to Benefit
-
AstraZeneca Rare Disease Drug Misses Phase 3 Target Hope Shifts to Subgroup Data
-
Over 22,000 New Cases in India AstraZeneca Gets CDSCO Green Light for Muscle-Invasive Bladder Cancer Drug
-
60 Percent Workforce Held by Top 10 Firms! China’s TCM Industry Faces Fierce Reshuffle as Private Leaders Expand Fast
Recommend Reading
-
Abbott to Market MSD’s Sitagliptin Brands in India Targeting 20 Percent of Diabetes Market
-
Eli Lilly to Appeal UK Rejection of Alzheimer's Drug Kisunla Impacting Thousands of Patients
-
Chinese Biopharma Giants Clash Over Patent Validity in 3.2 Billion RMB Market
-
Glenmark Launches Affordable OTC Eye Drop in US 50 Million Dollar Market
-
Venetoclax Falls Short in 15 Month MDS Survival Challenge but Hope Remains
-
Expected Short-term Peak Season Surge, This Week's Polyester Chip Market in China Shows High-level Fluctuations
-
Firm Costs and Weak Demand Lead to High-Level Fluctuations in the Chinese PTA Market
-
BDO market trend continues to rise in China
-
This Week's Styrene Market Fluctuates and Declines (3.30-4.3)
-
MTBE Market Trends: First Rise, Then Fall